Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

<jats:p> Eleven-nineteen leukemia (ENL) contains an epigenetic reader domain (YEATS domain) that recognizes lysine acylation on histone 3 and facilitates transcription initiation and elongation through its interactions with the super elongation complex (SEC) and the histone methyl transferase DOT1L. Although it has been known for its role as a fusion protein in mixed lineage leukemia (MLL), overexpression of native ENL, and thus dysregulation of downstream genes in acute myeloid leukemia (AML), has recently been implicated as a driver of disease that is reliant on the epigenetic reader activity of the YEATS domain. We developed a peptide displacement assay (histone 3 tail with acylated lysine) and screened a small-molecule library totaling more than 24,000 compounds for their propensity to disrupt the YEATS domain–histone peptide binding. Among these, we identified a first-in-class dual inhibitor of ENL ( K<jats:sub>d</jats:sub> = 745 ± 45 nM) and its paralog AF9 ( K<jats:sub>d</jats:sub> = 523 ± 53 nM) and performed “SAR by catalog” with the aim of starting the development of a chemical probe for ENL. </jats:p>

Original publication

DOI

10.1177/2472555218809904

Type

Journal article

Journal

SLAS DISCOVERY: Advancing the Science of Drug Discovery

Publisher

SAGE Publications

Publication Date

02/2019

Volume

24

Pages

133 - 141